CEO Dr. Hanadie Yousef discusses Juvena’s AI-enabled platform for mapping the therapeutic potential of stem cell secreted proteins and engineering restorative biologics for age-related and chronic diseases on the podcast Impact AI
Dr. Jeremy O’Connell, our CSO, participated as a panelist at the Gerontological Society of America (GSA) Annual Meeting, discussing the role of NIA programs in advancing JUV-161 from discovery to development and fostering innovation in aging research.
Thach Mai, Director of Discovery and Platform, and Priya Handa, Director of Translational Biology, were speakers at the 16th Drug Discovery Strategic Summit in San Francisco. Thach presented on our AI-enabled platform for therapeutic discovery, while Priya spoke about JUV-112, a novel approach to weight loss and metabolic health.
CEO Dr. Hanadie Yousef discusses Juvena’s AI-enabled proteomics and multimodal platform for decoding therapeutic secreted proteins on the “Leveraging Technology to Advance the Pipeline” panel at Longwood’s Boston CEO summit
CEO Dr. Hanadie Yousef was nominated to Founders Forum’s 100 Women Founders to Watch, which shines a light on 100 of the most exceptional women founders blazing a trail in the tech industry across UK & Europe, the United States, and Southeast Asia
Juvena is delighted to have had the opportunity to participate in our investor Bison’s AGM. CEO Dr. Yousef was on a panel focused on discussing the latest innovations in AI-driven drug discovery and development
CEO, Dr. Hanadie Yousef inspires the next generation of biotech entrepreneurs, in a fireside chat: Targeting the biology of aging to rejuvenate lives- Dr. Yousef’s journey through science research to launching Juvena for the Global Biotech Revolution
Juvena shares updates with the DM community about our muscle regenerating fusion protein, JUV-161 in the “Meet the Myotonic Dystrophy Drug Developers” webinar
